FDC Limited is a leading pharmaceutical company in India, engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). It is particularly noted for its expertise in oral rehydration solutions, energy drinks, antibiotics, and ophthalmic therapies.

The company has expanded its global footprint through two wholly-owned subsidiaries in the USA and UK, and a joint venture in South Africa. FDC is also setting up advanced manufacturing plants to enhance its production capabilities.

FDC has a strategic focus on innovation with ongoing projects like recombinant Granulocyte Colony Stimulating Factor and third-generation thrombolytes. It has received multiple regulatory approvals, including those from the US FDA and European agencies.

The company has executed multiple buybacks and mergers to optimize its equity structure, with significant acquisitions in South Africa, making Fair Deal Corporation Pharmaceutical SA (Pty) Ltd a subsidiary.

In recent years, FDC has diversified its nutraceuticals products, launching multiple energy and immunity-boosting drinks, aligning with modern health and wellness trends. New product launches and expansion into emerging markets continue to drive growth.